eBioscience

Developed within Affymetrix's eBioscience business, the PrimeFlow RNA Assay allows users to profile RNA and protein expression within the same cells.

Affymetrix subsidiary, eBioscience, enters into a multi-year distribution agreement with Birmingham, UK-based diagnostic tools supplier The Binding Site.

NEW YORK (GenomeWeb News) – Affymetrix reported after the close of the market on Wednesday that its third quarter revenues rose 1 percent year over year.

This story was originally posted on Aug. 1.
Affymetrix posted a 20 percent rise in second-quarter revenues last week, largely due to a contribution from its eBioscience business, but also driven by double-digit growth in genotyping array sales.

This article was originally posted on May 1.
An unanticipated decline in demand for gene expression microarrays has thwarted Affymetrix's return to growth and profitability and caused the firm to suspend its 2013 guidance, executives said last week.

Less than a year after Affymetrix bought eBioscience, the array vendor is finding ways to combine its background in microarray and branched-DNA genotyping and expression with eBio's flow cytometry reagents and multiplex immunoassay portfolios.

This story has been updated from an earlier version to include comments from Affymetrix.
Life Technologies and Affymetrix have ended two patent infringement suits connected with Affy subsidiary eBioscience, according to court documents.

This article was originally posted on Feb. 1

NEW YORK (GenomeWeb News) – Sequenom has acquired eBioscience's lease for office space in San Diego, it disclosed in a document filed with the US Securities and Exchange Commission this week.

SAN FRANCISCO — Illumina will not be the only array vendor submitting a cytogenetics-focused array to the US Food and Drug Administration for clearance this quarter.

Pages

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.